B · Normal
On August 30, the German pharmaceutical company Bayer announced that the Phase III REVEAL study of the PET radioactive tracer iodine-124 evazamide used for research will be announced as the latest breakthrough research at the 2026 European Society of Cardiology Annual Meeting (ESC 2026). This pivotal study was based on visual scan interpretation and achieved all primary endpoints in the sensitivity and specificity evaluation of cardiac amyloidosis diagnosis; the results of the Phase III study in patients with suspected cardiac amyloidosis were announced at the 2026 European Society of Cardiology Congress and simultaneously published in the Journal of the American Medical Association.
biopharmaceutical 🕐 2026-08-30 20:19
#bayer #EA #medicine #biopharmaceutical
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

On October 13, people familiar with the matter revealed that the logistics arm o 10-13 00:25 On October 12, Google and Flo Health announced a multi-year cooperation to focus 10-12 21:10 On October 12, Polish Deputy Energy Minister Wrochna said that Poland expected t 10-12 20:48 On October 12th, the CEO of Leapmotor International stated that discussions betw 10-12 18:39 [U.S. senators from both parties say the U.S.-Russian diesel agreement is illega 10-12 03:41 [India launches the first anti-dumping sunset review investigation on dicyclohex 10-10 15:18

Comments

0/500
Captcha (click to refresh)
No comments yet